Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board

Core Insights - Clairity has appointed Connie Lehman, MD, PhD, as CEO and Joe Kiani as Chairman of the Board, marking a significant leadership transition as the company focuses on clinical adoption and growth [1][2]. Company Developments - The leadership changes come after Clairity received FDA De Novo authorization for its AI-based mammography risk prediction platform, which is gaining traction with health systems globally [2]. - The company aims to enhance health outcomes, promote early disease prevention, and reduce healthcare costs through the responsible use of medical AI [3]. Strategic Vision - Dr. Lehman will oversee the company's strategy and operations, focusing on integrating Clairity's technology across diverse clinical environments [4]. - Joe Kiani emphasized that Clairity is positioned to lead advancements in breast cancer screening and prevention, leveraging the growing demand for its risk prediction platform [5]. Innovation and Impact - Clairity's platform analyzes standard mammograms to estimate a woman's five-year risk of developing breast cancer, facilitating personalized and proactive screening approaches [7]. - Dr. Lehman highlighted the need to shift the focus from detection to early risk identification and prevention, aiming to improve the effectiveness of screening and prevent advanced disease [5][6]. Financial Backing - In 2025, Clairity secured $43 million in Series B financing to support the commercialization and clinical adoption of its technology [8].